

Table 1

PIR, Males, Comparison Population is New York State exclusive of New York City

Site (ICD9 code)	observed	expected	PIR	SE(LPIR)*	SLPIR*
Oral Cavity and Digestive (140-159)	157	158.59	0.99	0.0670	-0.15
Oral Cavity and Pharynx (140-149)	22	20.70	1.06	0.2061	0.30
Digestive System (150-159)	135	137.90	0.98	0.0740	-0.29
Esophagus (150)	8	9.87	0.81	0.3428	-0.61
Stomach (151)	23	15.81	1.45	0.2024	1.85
Colon excl. Rectum (153)	56	54.90	1.02	0.1254	0.16
Rectum, Rectosigmoid and Anus (154)	25	28.71	0.87	0.1915	-0.72
Liver, Bile Duct, Gallbladder (155-156)	8	9.06	0.88	0.3474	-0.36
Pancreas (157)	14	16.29	0.86	0.2605	-0.58
Respiratory/Intrathoracic (160-165)	111	139.90	0.79	0.0843	-2.75
Larynx (161)	13	13.71	0.95	0.2707	-0.20
Trachea, Lung and Bronchus (162)	96	122.30	0.78	0.0915	-2.65
Bone, Connective Tissue, Skin and Breast (170-176)	35	24.10	1.45	0.1522	2.45
Melanoma of the Skin (172)	25	14.11	1.77	0.1916	2.99
Male Genital System (185-187)	145	131.76	1.10	0.0698	1.37
Prostate (185)	135	125.39	1.08	0.0724	1.02
Testis and Other Male Genital Organs (186-187)	10	6.37	1.57	0.2900	1.56
Urinary System (188-189,233.7)	75	63.88	1.17	0.1062	1.51
Urinary Bladder (188,233.7)	47	44.56	1.05	0.1367	0.39
Kidney and Other Urinary (189)	28	19.32	1.45	0.1813	2.05
Other & Unspecified Sites (190-199)	29	31.43	0.92	0.1722	-0.47
Brain and Other Nervous System (191-192)	7	9.86	0.71	0.3644	-0.94
Lymphomas (200-202)	29	26.94	1.08	0.1700	0.43
Leukemia (204-208)	13	15.31	0.85	0.2639	-0.62
Lymphoid Leukemia (204)	6	6.51	0.92	0.3918	-0.21
Other Leukemia (205-208)	7	8.80	0.80	0.3593	-0.64
Radiosensitive Solid	270	281.09	0.96	0.0437	-0.92
Non-Radiosensitive Solid	282	268.63	1.05	0.0417	1.17

* SE(LPIR) is the standard error of the log PIR; SLPIR is the standardized log PIR

Table 2

PIR, Females, Comparison Population is New York State exclusive of New York City

Site (ICD9 code)	observed	expected	PIR	SE(LPIR)*	SLPIR*
Oral Cavity and Digestive (140-159)	42	37.84	1.11	0.1292	0.81
Colon excl. Rectum (153)	16	16.35	0.98	0.2216	-0.10
Rectum, Rectosigmoid and Anus (154)	8	6.63	1.21	0.3260	0.57
Pancreas (157)	7	4.45	1.57	0.3430	1.32
Respiratory/Intrathoracic (160-165)	18	26.79	0.67	0.2072	-1.92
Bone, Connective Tissue, Skin and Breast (170-176)	80	74.12	1.08	0.0797	0.96
Female Breast (174)	73	67.74	1.08	0.0858	0.87
Cervix and Corpus Uterus (179,180,182)	14	20.35	0.69	0.2501	-1.50
Ovary (183)	12	10.11	1.19	0.2623	0.65
Urinary System (188-189,233.7)	7	8.61	0.81	0.3482	-0.60
Other & Unspecified Sites (190-199)	15	12.10	1.24	0.2322	0.93
Lymphomas (200-202)	7	7.88	0.89	0.3294	-0.36
Leukemia (204-208)	8	3.74	2.14	0.3331	2.28
Radiosensitive Solid	139	138.04	1.01	0.0450	0.15
Non-Radiosensitive Solid	50	53.45	0.94	0.1152	-0.58

* SE(LPIR) is the standard error of the log PIR; SLPIR is the standardized log PIR

Table 3
PIR, Males, Comparison Population is Nassau County

Site (ICD9 code)	observed	expected	PIR	SE(LPIR)*	SLPIR*
Oral Cavity and Digestive (140-159)	157	164.09	0.96	0.0670	-0.66
Oral Cavity and Pharynx (140-149)	22	18.96	1.16	0.2061	0.72
Digestive System (150-159)	135	145.14	0.93	0.0740	-0.98
Esophagus (150)	8	8.71	0.92	0.3428	-0.25
Stomach (151)	23	16.81	1.37	0.2024	1.55
Colon excl. Rectum (153)	56	58.73	0.95	0.1254	-0.38
Rectum, Rectosigmoid and Anus (154)	25	31.64	0.79	0.1915	-1.23
Liver, Bile Duct, Gallbladder (155-156)	8	8.91	0.90	0.3474	-0.31
Pancreas (157)	14	16.88	0.83	0.2605	-0.72
Respiratory/Intrathoracic (160-165)	111	118.17	0.94	0.0843	-0.74
Larynx (161)	13	11.81	1.10	0.2707	0.35
Trachea, Lung and Bronchus (162)	96	102.71	0.93	0.0915	-0.74
Bone, Connective Tissue, Skin and Breast (170-176)	35	29.63	1.18	0.1522	1.09
Melanoma of the Skin (172)	25	17.36	1.44	0.1916	1.90
Male Genital System (185-187)	145	135.87	1.07	0.0698	0.93
Prostate (185)	135	129.58	1.04	0.0724	0.57
Testis and Other Male Genital Organs (186-187)	10	6.28	1.59	0.2900	1.60
Urinary System (188-189,233.7)	75	68.31	1.10	0.1062	0.88
Urinary Bladder (188,233.7)	47	46.58	1.01	0.1367	0.07
Kidney and Other Urinary (189)	28	21.73	1.29	0.1813	1.40
Other & Unspecified Sites (190-199)	29	31.37	0.92	0.1722	-0.46
Brain and Other Nervous System (191-192)	7	10.46	0.67	0.3644	-1.10
Lymphomas (200-202)	29	30.26	0.96	0.1700	-0.25
Leukemia (204-208)	13	14.48	0.90	0.2639	-0.41
Lymphoid Leukemia (204)	6	6.27	0.96	0.3918	-0.11
Other Leukemia (205-208)	7	8.21	0.85	0.3593	-0.44
Radiosensitive Solid	270	271.23	1.00	0.0437	-0.10
Non-Radiosensitive Solid	282	276.26	1.02	0.0417	0.49

* SE(LPIR) is the standard error of the log PIR; SLPIR is the standardized log PIR

Table 4
PIR, Females, Comparison Population is Nassau County

Site (ICD9 code)	observed	expected	PIR	SE(LPIR)*	SLPIR*
Oral Cavity and Digestive (140-159)	42	37.44	1.12	0.1292	0.89
Colon excl. Rectum (153)	16	15.82	1.01	0.2216	0.05
Rectum, Rectosigmoid and Anus (154)	8	6.71	1.19	0.3260	0.54
Pancreas (157)	7	4.51	1.55	0.3430	1.28
Respiratory/Intrathoracic (160-165)	18	24.19	0.74	0.2072	-1.43
Bone, Connective Tissue, Skin and Breast (170-176)	80	79.17	1.01	0.0797	0.13
Female Breast (174)	73	71.83	1.02	0.0858	0.19
Cervix and Corpus Uterus (179,180,182)	14	18.62	0.75	0.2501	-1.14
Ovary (183)	12	10.49	1.14	0.2623	0.51
Urinary System (188-189,233.7)	7	8.23	0.85	0.3482	-0.46
Other & Unspecified Sites (190-199)	15	11.97	1.25	0.2322	0.97
Lymphomas (200-202)	7	8.28	0.85	0.3294	-0.51
Leukemia (204-208)	8	3.43	2.33	0.3331	2.54
Radiosensitive Solid	139	139.75	0.99	0.0450	-0.12
Non-Radiosensitive Solid	50	51.65	0.97	0.1152	-0.28

* SE(LPIR) is the standard error of the log PIR; SLPIR is the standardized log PIR

Table 5
PIR, Males, Comparison Population is Suffolk County

Site (ICD9 code)	observed	expected	PIR	SE(LPIR)*	SLPIR*
Oral Cavity and Digestive (140-159)	157	164.83	0.95	0.0670	-0.73
Oral Cavity and Pharynx (140-149)	22	20.07	1.10	0.2061	0.44
Digestive System (150-159)	135	144.76	0.93	0.0740	-0.94
Esophagus (150)	8	9.19	0.87	0.3428	-0.40
Stomach (151)	23	17.56	1.31	0.2024	1.33
Colon excl. Rectum (153)	56	61.02	0.92	0.1254	-0.68
Rectum, Rectosigmoid and Anus (154)	25	28.44	0.88	0.1915	-0.67
Liver, Bile Duct, Gallbladder (155-156)	8	9.05	0.88	0.3474	-0.36
Pancreas (157)	14	16.10	0.87	0.2605	-0.54
Respiratory/Intrathoracic (160-165)	111	140.92	0.79	0.0843	-2.83
Larynx (161)	13	14.24	0.91	0.2707	-0.34
Trachea, Lung and Bronchus (162)	96	122.23	0.79	0.0915	-2.64
Bone, Connective Tissue, Skin and Breast (170-176)	35	29.29	1.20	0.1522	1.17
Melanoma of the Skin (172)	25	17.07	1.46	0.1916	1.99
Male Genital System (185-187)	145	119.40	1.21	0.0698	2.79
Prostate (185)	135	113.61	1.19	0.0724	2.38
Testis and Other Male Genital Organs (186-187)	10	5.78	1.73	0.2900	1.89
Urinary System (188-189,233.7)	75	65.69	1.14	0.1062	1.25
Urinary Bladder (188,233.7)	47	45.81	1.03	0.1367	0.19
Kidney and Other Urinary (189)	28	19.88	1.41	0.1813	1.89
Other & Unspecified Sites (190-199)	29	31.85	0.91	0.1722	-0.54
Brain and Other Nervous System (191-192)	7	10.04	0.70	0.3644	-0.99
Lymphomas (200-202)	29	26.01	1.11	0.1700	0.64
Leukemia (204-208)	13	14.57	0.89	0.2639	-0.43
Lymphoid Leukemia (204)	6	5.64	1.06	0.3918	0.16
Other Leukemia (205-208)	7	8.93	0.78	0.3593	-0.68
Radiosensitive Solid	270	289.96	0.93	0.0437	-1.63
Non-Radiosensitive Solid	282	262.02	1.08	0.0417	1.76

* SE(LPIR) is the standard error of the log PIR; SLPIR is the standardized log PIR

Table 6
PIR, Females, Comparison Population is Suffolk County

Site (ICD9 code)	observed	expected	PIR	SE(LPIR)*	SLPIR*
Oral Cavity and Digestive (140-159)	42	39.09	1.07	0.1292	0.56
Colon excl. Rectum (153)	16	16.71	0.96	0.2216	-0.20
Rectum, Rectosigmoid and Anus (154)	8	6.87	1.16	0.3260	0.47
Pancreas (157)	7	4.91	1.43	0.3430	1.03
Respiratory/Intrathoracic (160-165)	18	27.81	0.65	0.2072	-2.10
Bone, Connective Tissue, Skin and Breast (170-176)	80	74.52	1.07	0.0797	0.89
Female Breast (174)	73	67.09	1.09	0.0858	0.98
Cervix and Corpus Uterus (179,180,182)	14	19.60	0.71	0.2501	-1.35
Ovary (183)	12	9.50	1.26	0.2623	0.89
Urinary System (188-189,233.7)	7	8.59	0.82	0.3482	-0.59
Other & Unspecified Sites (190-199)	15	12.17	1.23	0.2322	0.90
Lymphomas (200-202)	7	7.37	0.95	0.3294	-0.16
Leukemia (204-208)	8	3.30	2.42	0.3331	2.66
Radiosensitive Solid	139	137.83	1.01	0.0450	0.19
Non-Radiosensitive Solid	50	54.94	0.91	0.1152	-0.82

* SE(LPIR) is the standard error of the log PIR; SLPIR is the standardized log PIR

Table 7

PIR, Males, Comparison Population is New York State exclusive of New York City - Salaried Workers

Site (ICD9 code)	observed	expected	PIR	SE(LP <small>IR</small>) [*]	SL <small>PIR</small> [*]
Oral Cavity and Digestive (140-159)	88	79.90	1.10	0.0861	1.12
Oral Cavity and Pharynx (140-149)	12	10.91	1.10	0.2709	0.35
Digestive System (150-159)	76	68.99	1.10	0.0953	1.02
Stomach (151)	14	7.93	1.77	0.2570	2.21
Colon excl. Rectum (153)	29	26.99	1.07	0.1727	0.42
Rectum, Rectosigmoid and Anus (154)	15	14.45	1.04	0.2415	0.15
Pancreas (157)	7	8.24	0.85	0.3673	-0.44
Respiratory/Intrathoracic (160-165)	43	71.24	0.60	0.1375	-3.67
Bone, Connective Tissue, Skin and Breast (170-176)	18	12.65	1.42	0.2103	1.68
Melanoma of the Skin (172)	15	7.50	2.00	0.2442	2.84
Male Genital System (185-187)	75	65.54	1.14	0.0949	1.42
Urinary System (188-189,233.7)	41	32.41	1.26	0.1388	1.69
Urinary Bladder (188,233.7)	25	22.31	1.12	0.1802	0.63
Kidney and Other Urinary (189)	16	10.10	1.58	0.2351	1.96
Other & Unspecified Sites (190-199)	15	16.10	0.93	0.2200	-0.32
Lymphomas (200-202)	14	13.91	1.01	0.2450	0.03
Leukemia (204-208)	6	7.68	0.78	0.3858	-0.64
Radiosensitive Solid	136	142.07	0.96	0.0606	-0.72
Non-Radiosensitive Solid	144	135.80	1.06	0.0569	1.03

* SE(LPIR) is the standard error of the log PIR; SLPIR is the standardized log PIR

Table 8

PIR, Males, Comparison Population is New York State exclusive of New York City - Wage or Hourly Workers

Site (ICD9 code)	observed	expected	PIR	SE(LPIR)*	SLPIR*
Oral Cavity and Digestive (140-159)	69	78.69	0.88	0.1015	-1.30
Oral Cavity and Pharynx (140-149)	10	9.79	1.02	0.3003	0.07
Digestive System (150-159)	59	68.90	0.86	0.1115	-1.39
Stomach (151)	9	7.89	1.14	0.3212	0.41
Colon excl. Rectum (153)	27	27.91	0.97	0.1741	-0.19
Rectum, Rectosigmoid and Anus (154)	10	14.25	0.70	0.3031	-1.17
Pancreas (157)	7	8.06	0.87	0.3680	-0.38
Respiratory/Intrathoracic (160-165)	68	68.67	0.99	0.1028	-0.09
Bone, Connective Tissue, Skin and Breast (170-176)	17	11.45	1.48	0.1973	2.00
Melanoma of the Skin (172)	10	6.60	1.51	0.2933	1.42
Male Genital System (185-187)	70	66.22	1.06	0.0991	0.56
Urinary System (188-189,233.7)	34	31.46	1.08	0.1580	0.49
Urinary Bladder (188,233.7)	22	22.25	0.99	0.2009	-0.06
Kidney and Other Urinary (189)	12	9.22	1.30	0.2742	0.96
Other & Unspecified Sites (190-199)	14	15.33	0.91	0.2497	-0.36
Lymphomas (200-202)	15	13.03	1.15	0.2233	0.63
Leukemia (204-208)	7	7.63	0.92	0.3446	-0.25
Radiosensitive Solid	134	139.02	0.96	0.0610	-0.60
Non-Radiosensitive Solid	138	132.82	1.04	0.0588	0.65

* SE(LPIR) is the standard error of the log PIR; SLPIR is the standardized log PIR

Table 9

PIR, Females, Comparison Population is New York State exclusive of New York City - Salaried Workers

Site (ICD9 code)	observed	expected	PIR	SE(LPIR)*	SLPIR*
Oral Cavity and Digestive (140-159)	17	13.35	1.27	0.1900	1.27
Respiratory/Intrathoracic (160-165)	9	9.86	0.91	0.2654	-0.34
Bone, Connective Tissue, Skin and Breast (170-176)	31	28.33	1.09	0.1079	0.84
Radiosensitive Solid	56	51.48	1.09	0.0619	1.36
Non-Radiosensitive Solid	14	19.60	0.71	0.2159	-1.56

* SE(LPIR) is the standard error of the log PIR; SLPIR is the standardized log PIR

Table 10

PIR, Females, Comparison Population is New York State exclusive of New York City - Wage or Hourly Workers

Site (ICD9 code)	observed	expected	PIR	SE(LPIR)*	SLPIR*
Oral Cavity and Digestive (140-159)	25	24.48	1.02	0.1596	0.13
Respiratory/Intrathoracic (160-165)	9	16.93	0.53	0.2883	-2.19
Bone, Connective Tissue, Skin and Breast (170-176)	49	45.79	1.07	0.0986	0.69
Radiosensitive Solid	83	86.56	0.96	0.0599	-0.70
Non-Radiosensitive Solid	36	33.85	1.06	0.1297	0.47

• SE(LPIR) is the standard error of the log PIR; SLPIR is the standardized log PIR

Table 11. Hypothetical Example - Overall Rate in the Study Population is the Same as in the Comparison Population

Cancer Site	Comparison Population			Study Population			Comparison Measure	
	Number of Cases ¹	Rate per 100,000 ²	Proportion of Cases	Observed Cases ³	Expected Cases ⁴	Rate per 100,000 ⁵	PIR	Rate Ratio
Oral & Digestive	5552	100.45	0.213	105	109.05	96.72	0.96	0.96
Respiratory	3705	67.03	0.142	45	72.77	41.45	0.62	0.62
Breast	7499	135.68	0.287	183	147.29	168.57	1.24	1.24
Cervix & Corpus	2185	39.53	0.084	37	42.92	34.08	0.86	0.86
Ovary	1095	19.81	0.042	33	21.51	30.40	1.53	1.53
Urinary	1320	23.88	0.051	20	25.93	18.42	0.77	0.77
Lymphomas	1141	20.64	0.044	18	22.41	16.58	0.80	0.80
Leukemias	595	10.77	0.023	12	11.69	11.05	1.03	1.03
Other	3026	54.75	0.116	60	59.44	55.27	1.01	1.01
Total	26118	472.55		513	513.00	472.55	1.00	1.00

1) The comparison population represents females in New York State exclusive of New York City, 1993-1997.

2) Rates are crude rates (i.e., they are not age adjusted).

3) Distribution of observed cases in the hypothetical study population is fixed (i.e. these numbers were "observed").

4) The expected number of cases is calculated by applying the proportions from the comparison population to the total number of cases in the study population (i.e., for breast, 0.287×513); no adjustment for age or calendar time is being made.

5) Assuming equal overall rates results in fixing the person years at risk in the study population (i.e., the denominator of the rate is fixed at 108,560).

Table 12. Hypothetical Example - Overall Rate in the Study Population is 20% Higher than in the Comparison Population

Cancer Site	Comparison Population			Study Population			Comparison Measure	
	Number of Cases ¹	Rate per 100,000 ²	Proportion of Cases	Observed Cases ³	Expected Cases ⁴	Rate per 100,000 ⁵	PIR	Rate Ratio
Oral & Digestive	5552	100.45	0.213	105	109.05	116.06	0.96	1.16
Respiratory	3705	67.03	0.142	45	72.77	49.74	0.62	0.74
Breast	7499	135.68	0.287	183	147.29	202.28	1.24	1.49
Cervix & Corpus	2185	39.53	0.084	37	42.92	40.90	0.86	1.03
Ovary	1095	19.81	0.042	33	21.51	36.48	1.53	1.84
Urinary	1320	23.88	0.051	20	25.93	22.11	0.77	0.93
Lymphomas	1141	20.64	0.044	18	22.41	19.90	0.80	0.96
Leukemias	595	10.77	0.023	12	11.69	13.26	1.03	1.23
Other	3026	54.75	0.116	60	59.44	66.32	1.01	1.21
Total	26118	472.55		513	513.00	567.06	1.00	1.20

1) The comparison population represents females in New York State exclusive of New York City, 1993-1997.

2) Rates are crude rates (i.e., they are not age adjusted).

3) Distribution of observed cases in the hypothetical study population is fixed (i.e. these numbers were "observed").

4) The expected number of cases is calculated by applying the proportions from the comparison population to the total number of cases in the study population (i.e., for breast, 0.287×513); no adjustment for age or calendar time is being made.

5) Assuming the overall rate in the study population is 20% higher than in the comparison population results in fixing the person years at risk in the study population (i.e., the denominator of the rate is fixed at 90,467).

Table 13. Hypothetical Example - Overall Rate in the Study Population is 20% Lower than in the Comparison Population								
Cancer Site	Comparison Population			Study Population			Comparison Measure	
	Number of Cases ¹	Rate per 100,000 ²	Proportion of Cases	Observed Cases ³	Expected Cases ⁴	Rate per 100,000 ⁵	PIR	Rate Ratio
Oral & Digestive	5552	100.45	0.213	105	109.05	77.38	0.96	0.77
Respiratory	3705	67.03	0.142	45	72.77	33.16	0.62	0.49
Breast	7499	135.68	0.287	183	147.29	134.86	1.24	0.99
Cervix & Corpus	2185	39.53	0.084	37	42.92	27.27	0.86	0.69
Ovary	1095	19.81	0.042	33	21.51	24.32	1.53	1.23
Urinary	1320	23.88	0.051	20	25.93	14.74	0.77	0.62
Lymphomas	1141	20.64	0.044	18	22.41	13.26	0.80	0.64
Leukemias	595	10.77	0.023	12	11.69	8.84	1.03	0.82
Other	3026	54.75	0.116	60	59.44	44.22	1.01	0.81
Total	26118	472.55		513	513.00	378.04	1.00	0.80
1) The comparison population represents females in New York State exclusive of New York City, 1993-1997.								
2) Rates are crude rates (i.e., they are not age adjusted).								
3) Distribution of observed cases in the hypothetical study population is fixed (i.e. these numbers were "observed").								
4) The expected number of cases is calculated by applying the proportions from the comparison population to the total number of cases in the study population (i.e., for breast, 0.287x513); no adjustment for age or calendar time is being made.								
5) Assuming the overall rate in the study population is 20% lower than in the comparison population results in fixing the person years at risk in the study population (i.e., the denominator of the rate is fixed at 135,700).								